{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:51:21Z","timestamp":1790077881620,"version":"4.0.1"},"reference-count":235,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2000,12,1]],"date-time":"2000-12-01T00:00:00Z","timestamp":975628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2000,12]]},"DOI":"10.1054\/drup.2000.0171","type":"journal-article","created":{"date-parts":[[2002,9,19]],"date-time":"2002-09-19T14:55:24Z","timestamp":1032447324000},"page":"364-383","source":"Crossref","is-referenced-by-count":24,"title":["The role of murine models in the development of antifungal therapy for systemic mycoses"],"prefix":"10.1054","volume":"3","author":[{"given":"John R.","family":"Graybill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1054\/drup.2000.0171_RF1","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/infdis\/145.2.748","article-title":"Treatment of murine cryptococcosis with liposome-associated amphotericin B","volume":"145","author":"Graybill","year":"1982","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF2","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1164\/arrd.1982.125.5.610","article-title":"Amphotericin B in liposomes: a novel therapy for histoplasmosis","volume":"125","author":"Taylor","year":"1982","journal-title":"Am Rev Respir Dis"},{"key":"10.1054\/drup.2000.0171_RF3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/AAC.26.2.170","article-title":"Efficacy of liposome-intercalculated amphotericin B in the treatment of systemic candidiasis in mice","volume":"26","author":"Tremblay","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF4","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1128\/AAC.44.4.950-957.2000","article-title":"Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits","volume":"44","author":"Groll","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF5","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1128\/AAC.42.7.1722","article-title":"Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans","volume":"42","author":"Hossain","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF6","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/infdis\/164.5.1003","article-title":"Liposomal hamycin: reduced toxicity and improved antifungal efficacy in vitro and in vivo","volume":"164","author":"Mehta","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/AAC.43.3.471","article-title":"In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus","volume":"43","author":"Otsubo","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF8","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.44.6.1463-1469.2000","article-title":"Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model","volume":"44","author":"Zarif","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/infdis\/133.2.168","article-title":"Comparison of amphotericin B and amphotericin B methyl ester: efficacy in murine coccidioidomycosis and toxicity","volume":"133","author":"Lawrence","year":"1976","journal-title":"J Infect Dis."},{"key":"10.1054\/drup.2000.0171_RF10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/infdis\/146.2.125","article-title":"Leukoencephalopathy in patients with amphotericin B methyl ester","volume":"146","author":"Ellis","year":"1982","journal-title":"J Infect Dis."},{"key":"10.1054\/drup.2000.0171_RF11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/infdis\/146.2.173","article-title":"Amphotericin B methyl ester and leukoencephalopathy: the other side of the coin","volume":"146","author":"Hoeprich","year":"1982","journal-title":"J Infect Dis."},{"key":"10.1054\/drup.2000.0171_RF12","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1093\/clinids\/14.Supplement_1.S114","article-title":"Clinical use of amphotericin B and derivatives: lore, mystique, and fact","volume":"14 Suppl. 1","author":"Hoeprich","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1128\/AAC.37.3.419","article-title":"Comparative neurotoxicities of amphotericin B and its mono-methyl ester derivative in rats","volume":"37","author":"Reuhl","year":"1993","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1054\/drup.2000.0171_RF14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1128\/AAC.26.4.446","article-title":"Comparative pharmacokinetics of SCH 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys","volume":"26","author":"Kim","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1128\/AAC.28.6.751","article-title":"Comparison of amphotericin B and-N-D-Ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis andCandida albicans endocarditis with pyelonephritis","volume":"28","author":"Perfect","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1128\/AAC.26.1.108","article-title":"Ornithyl amphotericin methyl ester treatment of experimental candidiasis in rats","volume":"26","author":"Galgiani","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF17","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1128\/AAC.36.12.2722","article-title":"Activity of MS-8209, a nonester amphotericin B derivitive, in treatment of experimental systemic mycoses","volume":"36","author":"Saint-Julien","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF18","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1128\/AAC.41.8.1775","article-title":"Treatment of murine disseminated candidiasis with L-743, 872","volume":"41","author":"Graybill","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF19","first-page":"abstract1043,","article-title":"Comparative activity in vivo and toxicity of a new polyene, BRL 4954A and amphotericin B (amB)","author":"Hunter","year":"1992","journal-title":"Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology,"},{"key":"10.1054\/drup.2000.0171_RF20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM199401273300407","article-title":"Oral azole drugs as systemic antifungal therapy","volume":"330","author":"Como","year":"1994","journal-title":"N Engl J Med."},{"key":"10.1054\/drup.2000.0171_RF21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.6.1.1","article-title":"Compounds active against cell walls of medically important fungi","volume":"6","author":"Hector","year":"1993","journal-title":"Clin Microbiol Rev"},{"key":"10.1054\/drup.2000.0171_RF22","series-title":"Experimental Models in Antimicrobial Chemotherapy. 3ed","article-title":"Animal models for treatment of cryptococcosis","author":"Graybill","year":"1986"},{"key":"10.1054\/drup.2000.0171_RF23","first-page":"abstract F110","article-title":"Efficacy of KY-62 (KY) in murine cryptococcosis and candidiasis","author":"Najvar","year":"1995","journal-title":"Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy."},{"key":"10.1054\/drup.2000.0171_RF24","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1164\/ajrccm\/142.3.512","article-title":"Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304","volume":"142","author":"DeFaveri","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1054\/drup.2000.0171_RF25","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1128\/AAC.41.9.1937","article-title":"Treatment of murine Candida krusei or Candida glabrata infection with L-743,872","volume":"41","author":"Graybill","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF26","first-page":"abstract F99","article-title":"Treatment of murine pulmonary aspergillosis with SCH56592 (SCH)","author":"Graybill","year":"1996","journal-title":"Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy."},{"key":"10.1054\/drup.2000.0171_RF27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/00362178585380321","article-title":"Itraconazole treatment of murine aspergillosis","volume":"23","author":"Graybill","year":"1985","journal-title":"J Med Vet Mycol"},{"key":"10.1054\/drup.2000.0171_RF28","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1128\/AAC.35.10.2128","article-title":"Treatment of murine invasive candidiasis with amphotericin B and cilofungin: evidence of enhanced activity with combination therapy","volume":"35","author":"Sugar","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF29","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1128\/AAC.39.4.996","article-title":"Treatment of murine pulmonary blastomycosis with SCH 51048, a broad-spectrum triazole antifungal agent","volume":"39","author":"Sugar","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF30","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1128\/AAC.39.5.1169","article-title":"Activities of the triazole SCH 51048 against Coccidioides immitis in vitro and in vivo","volume":"39","author":"Clemons","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF31","first-page":"abstract F87","article-title":"Treatment of murine cryptococcal meningitis with UR-9751 and UR-9746)","author":"Restrepo","year":"1995","journal-title":"Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy."},{"key":"10.1054\/drup.2000.0171_RF32","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1128\/AAC.42.3.528","article-title":"Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococal meningitis","volume":"42","author":"Diamond","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF33","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1128\/AAC.39.4.924","article-title":"Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice","volume":"39","author":"Graybill","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF34","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1128\/AAC.39.10.2197","article-title":"Fluconazole treatment of Candida albicans infection in mice: Does in vitro susceptibility predict in vivo response?","volume":"39","author":"Graybill","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/clinids\/20.1.115","article-title":"Importance of Candida species other than C. albicans as pathogens in oncology patients","volume":"20","author":"Wingard","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.39.1.1","article-title":"Resistance of Candida species to fluconazole","volume":"39","author":"Rex","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0732-8893(98)00160-6","article-title":"Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States","volume":"33","author":"Pfaller","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF38","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/infdis\/147.5.939","article-title":"Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B","volume":"146","author":"Lopez-Berestein","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF39","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/AAC.25.3.366","article-title":"Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B and a muramyl dipeptide analog, alone and in combination","volume":"25","author":"Lopez-Berestein","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/jac\/28.suppl_B.63","article-title":"Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome)","volume":"28 Suppl B","author":"Adler-Moore","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1054\/drup.2000.0171_RF41","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/infdis\/169.5.1057","article-title":"Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis","volume":"169","author":"Pahl","year":"1994","journal-title":"J Infect Dis."},{"key":"10.1054\/drup.2000.0171_RF42","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/infdis\/150.2.278","article-title":"Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice","volume":"150","author":"Lopez-Berestein","year":"1984","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF43","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1128\/AAC.38.11.2660","article-title":"Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae andCandida krusei infection in neutropenic mice","volume":"38","author":"Karyotakis","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF44","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1128\/AAC.39.9.1954","article-title":"Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice","volume":"39","author":"Van Etten","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF45","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1128\/AAC.42.9.2431","article-title":"Superior efficacy of liposomal amphottericin B with prolonged circulation in blood in the treatment of severe candidiasis in leukopenic mice","volume":"42","author":"Van Etten","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/AAC.33.1.16","article-title":"Effect of attachment of anticandidal antibody to the surface of liposomes encapsulating amphotericin B in the treatment of murine candidiasis","volume":"33","author":"Hospenthal","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF47","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1128\/AAC.43.10.2463","article-title":"Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits","volume":"43","author":"Groll","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF48","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1128\/AAC.40.5.1317","article-title":"Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model","volume":"40","author":"Barchiesi","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF49","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1128\/AAC.42.11.2938","article-title":"Fluconazole versus Candida albicans: a complex relationship","volume":"42","author":"Graybill","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF50","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/CMR.11.2.382","article-title":"Clinical, cellular, and molecular factors that contribute to antifungal drug resistance","volume":"11","author":"White","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"10.1054\/drup.2000.0171_RF51","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1128\/AAC.40.6.1342","article-title":"Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model","volume":"40","author":"Valentin","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF52","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1128\/AAC.41.2.233","article-title":"Activity of a new triazole, SCH56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevesiae","volume":"41","author":"Pfaller","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF53","first-page":"abstract F88","article-title":"In vitro activity of Schering 56592, compared with fluconazole and itraconazole against Candida spp","author":"Law","year":"1996","journal-title":"Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy."},{"key":"10.1054\/drup.2000.0171_RF54","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1128\/AAC.41.8.1775","article-title":"Treatment of murine disseminated candidiasis with L-743,872","volume":"41","author":"Graybill","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF55","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1128\/AAC.38.7.1604","article-title":"Treatment of disseminated Torulopsis glabrata infection with DO870 and amphotericin B","volume":"38","author":"Atkinson","year":"1994","journal-title":"AntimicrobAgents Chemother"},{"key":"10.1054\/drup.2000.0171_RF56","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.37.9.1847","article-title":"Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients","volume":"37","author":"Wingard","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF57","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/infdis\/168.5.1311","article-title":"Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice","volume":"168","author":"Karyotakis","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF58","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1056\/NEJM199110313251803","article-title":"Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated with prophylactically with fluconazole","volume":"325","author":"Wingard","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1054\/drup.2000.0171_RF59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1179\/joc.1999.11.1.34","article-title":"Antifungal activity of voriconazole (UK-109,496), fluconazole, and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model","volume":"11","author":"Ghannoum","year":"1999","journal-title":"J Chemother"},{"key":"10.1054\/drup.2000.0171_RF60","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1128\/AAC.39.12.2689","article-title":"In vitro activity of a new pneumocandin antifungal agent, L-733,560, against azole- susceptible and -resistantCandida and Torulopsis species","volume":"39","author":"Vazquez","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/AAC.44.1.57-62.2000","article-title":"In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi","volume":"44","author":"Tawara","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF62","article-title":"In vitro susceptibility of Candida blood stream isolates to a new echinocandin derivative, LY303366 and comparative antifungal agents","author":"Pfaller","year":"1996","journal-title":"Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy."},{"key":"10.1054\/drup.2000.0171_RF63","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1128\/AAC.41.5.1156","article-title":"In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates","volume":"41","author":"Uzun","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF64","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1128\/AAC.44.6.1728-1730.2000","article-title":"Efficacy of FK4634, a 1,3-beta-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice","volume":"44","author":"Maesaki","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF65","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/AAC.44.3.614-618.2000","article-title":"Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis","volume":"44","author":"Ikeda","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF66","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1128\/AAC.43.9.2148","article-title":"Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits","volume":"43","author":"Petraitiene","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF67","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1128\/AAC.26.4.527","article-title":"Itraconazole, a new triazole that is orally active in aspergillosis","volume":"26","author":"Van Cutsem","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF68","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1128\/AAC.36.12.2681","article-title":"Saperconazole therapy in a rabbit model of invasive aspergillosis","volume":"36","author":"Patterson","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF69","first-page":"582","article-title":"Efficacy of SCH56592 treatment and prevention of invasive pulmonary aspergillosis in persistently neutropenic rabbits","author":"Petratiene","year":"1999","journal-title":"Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy."},{"key":"10.1054\/drup.2000.0171_RF70","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1128\/AAC.38.6.1303","article-title":"Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma","volume":"38","author":"Berenguer","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF71","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/infdis\/147.1.160","article-title":"Inhibition of monocyte-mediated damage to fungal hyphae by steroid hormones","volume":"147","author":"Diamond","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF72","first-page":"313","article-title":"Damage to hyphal forms of fungi by human leukocytes in vitro","volume":"91","author":"Diamond","year":"1978","journal-title":"Am J Pathol."},{"key":"10.1054\/drup.2000.0171_RF73","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1164\/ajrccm.152.3.7663787","article-title":"Pathogenesis of pulmonary aspergillosis \u2013 granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression","volume":"152","author":"Berenguer","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1054\/drup.2000.0171_RF74","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/513943","article-title":"Invasive aspergillosis","volume":"26","author":"Denning","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF75","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jac\/42.4.539","article-title":"SCH56592 treatment of murine invasive aspergillosis","volume":"42","author":"Graybill","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1054\/drup.2000.0171_RF76","first-page":"292","article-title":"Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH28191","volume":"129","author":"Graybill","year":"1984","journal-title":"Am Rev Resp Dis"},{"key":"10.1054\/drup.2000.0171_RF77","first-page":"abstract F94","article-title":"In vitro-in vivo correlations for the azole antifungals SCH56592 (56592), SCH39304 (39304), fluconazole (FCZ) and itraconazole (ITZ) in candidiasis and aspergillosis","author":"Miller","year":"1996","journal-title":"Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy."},{"key":"10.1054\/drup.2000.0171_RF78","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1128\/AAC.44.2.378-381.2000","article-title":"Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids","volume":"44","author":"Clemons","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF79","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1128\/AAC.41.6.1364","article-title":"Itraconazole resistance in Aspergillus fumigatus","volume":"41","author":"Denning","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF80","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1128\/AAC.42.10.2467","article-title":"Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression","volume":"42","author":"Graybill","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF81","first-page":"abstract F33","article-title":"In vitro antifungal activity of L-743872 against a variety of moulds","author":"Del Poeta","year":"1996","journal-title":"Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy."},{"key":"10.1054\/drup.2000.0171_RF82","first-page":"abstract F31","article-title":"In vitro studies with L-743,872, a water soluble pneumocandin: a comparative study","author":"Espinel-Ingroff","year":"1996","journal-title":"Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy."},{"key":"10.1054\/drup.2000.0171_RF83","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1128\/AAC.39.5.1077","article-title":"Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis","volume":"39","author":"Abruzzo","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF84","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1128\/AAC.41.11.2333","article-title":"Evaluation of the echinocandin antifungal MK-0991 (L-743,872) efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis","volume":"41","author":"Abruzzo","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF85","first-page":"abstract F38","article-title":"Low doses of pneumocandin L-743872, are effective in prevention and treatment in an animal model of pulmonary aspergillosis","author":"Bernard","year":"1996","journal-title":"Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy."},{"key":"10.1054\/drup.2000.0171_RF86","first-page":"abstract F28","article-title":"In vitro activity of L-743872 against putatively amphotericin B (AmB) and fluconazole (Flu)-resistant Candida isolates","author":"Nelson","year":"1996","journal-title":"Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy."},{"key":"10.1054\/drup.2000.0171_RF87","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1128\/AAC.44.3.619-621.2000","article-title":"Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis","volume":"44","author":"Matsumoto","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF88","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1128\/AAC.42.11.2898","article-title":"Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits","volume":"42","author":"Petraitis","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF89","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1128\/AAC.39.8.1784","article-title":"Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis","volume":"39","author":"Kurtz","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF90","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/AAC.42.4.873","article-title":"Efficacy of LY303366 against amphotericin B susceptible and resistant Aspergillus fumigatus in a murine model of invasive aspergillosis","volume":"42","author":"Verweij","year":"1998","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1054\/drup.2000.0171_RF91","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1099\/00222615-48-12-1087","article-title":"In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis","volume":"48","author":"Dannaoui","year":"1999","journal-title":"J Med Microbiol"},{"key":"10.1054\/drup.2000.0171_RF92","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/jac\/40.3.401","article-title":"Correlation between in-vitro susceptibility testing to itraconazole abd in-vivo outcome of Aspergillus fumigatus infection","volume":"40","author":"Denning","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1054\/drup.2000.0171_RF93","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/AAC.41.1.13","article-title":"Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs","volume":"41","author":"Martin","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF94","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/AAC.40.1.86","article-title":"Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis","volume":"40","author":"George","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF95","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1128\/JCM.29.7.1317-1322.1991","article-title":"Model of recurrent pulmonary aspergillosis in rats","volume":"29","author":"Niki","year":"1991","journal-title":"J Clin Microbiol"},{"key":"10.1054\/drup.2000.0171_RF96","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1128\/AAC.37.11.2307","article-title":"Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis","volume":"37","author":"Patterson","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF97","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/infdis\/169.2.356","article-title":"Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-manitol and serum galactomannan as markers of infection","volume":"169","author":"Francis","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF98","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1128\/AAC.35.4.615","article-title":"Amphotericin B lipid complex therapy of experimental fungal infections in mice","volume":"35","author":"Clark","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF99","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1128\/AAC.38.3.518","article-title":"Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis","volume":"38","author":"Allende","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF100","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1128\/AAC.41.10.2238","article-title":"Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice","volume":"41","author":"Wallace","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF101","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1128\/AAC.43.11.2592","article-title":"Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B","volume":"43","author":"Denning","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF102","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1128\/AAC.44.3.540-545.2000","article-title":"Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats","volume":"44","author":"Van Etten","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF103","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/AAC.42.1.40","article-title":"Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice","volume":"42","author":"Otsubo","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF104","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/AAC.44.3.780-782.2000","article-title":"Efficacy of SCH56592 in a rabbit model of invasive aspergillosis","volume":"44","author":"Kirkpatrick","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF105","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.39.5.1065","article-title":"Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy","volume":"39","author":"Walsh","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF106","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1128\/AAC.42.9.2279","article-title":"Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans","volume":"42","author":"Dominguez","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF107","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1128\/AAC.42.11.2863","article-title":"Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi","volume":"42","author":"Herreros","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF108","first-page":"abstract J-74","article-title":"Pharmacodynamic\/pharmacokinetic (PK\/PD) study of sordarin derivatives in a lethal C albicans infection in mice","author":"Aviles","year":"1998","journal-title":"Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy."},{"key":"10.1054\/drup.2000.0171_RF109","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1128\/AAC.43.7.1716","article-title":"Activities of sordarins in murine histoplasmosis","volume":"43","author":"Graybill","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF110","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1128\/AAC.44.7.1874-1877.2000","article-title":"Efficacies of sordarin derivatives GM193663, GM211676, and GM237354 in a murine model of systemic coccidioidomycosis","volume":"44","author":"Clemons","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF111","first-page":"297","article-title":"Sordarins as antifungal compounds","volume":"1","author":"Gargallo-Viola","year":"1999","journal-title":"Curr Opin Anti-Infect Invest Drugs"},{"key":"10.1054\/drup.2000.0171_RF112","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1164\/arrd.1983.127.5.636","article-title":"Pulmonary cryptococcosis in the rat","volume":"127","author":"Graybill","year":"1983","journal-title":"Am Rev Resp Dis"},{"key":"10.1054\/drup.2000.0171_RF113","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jac\/18.2.261","article-title":"Treatment of cryptococcal meningitis in mice with fluconazole","volume":"18","author":"Fernandez","year":"1986","journal-title":"J Antimicrob Chemother"},{"key":"10.1054\/drup.2000.0171_RF114","series-title":"Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents.","article-title":"Fluconazole efficacy in animal models of mycotic diseases","author":"Graybill","year":"1987"},{"key":"10.1054\/drup.2000.0171_RF115","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/infdis\/140.4.546","article-title":"Host defense in cryptococcosis. Protection of nude mice by thymus transplantation","volume":"140","author":"Graybill","year":"1979","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF116","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1128\/AAC.41.7.1589","article-title":"Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis","volume":"41","author":"Ding","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF117","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1128\/AAC.40.9.2178","article-title":"Effect of fluconazole on antifungal activity of flucytosine in murine cryptococcal meningitis","volume":"40","author":"Larsen","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF118","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1128\/AAC.43.2.413","article-title":"An alternative animal model for comparison of treatments for cryptococcal meningitis","volume":"43","author":"Najvar","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF119","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/infdis\/168.2.508","article-title":"Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis","volume":"168","author":"Velez","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF120","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.42.4.899","article-title":"Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for treatment of systmic murine cryptococcosis","volume":"42","author":"Clemons","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF121","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1128\/AAC.14.5.659","article-title":"Interaction of chemotherapy and immune defense in experimental murine cryptococcosis","volume":"14","author":"Graybill","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF122","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/0003-4819-103-4-533","article-title":"Cryptococcosis in the acquired immunodeficiency syndrome","volume":"103","author":"Kovacs","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1054\/drup.2000.0171_RF123","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1128\/AAC.34.11.2055","article-title":"Improvements of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes","volume":"34","author":"Dromer","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF124","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1128\/AAC.36.12.2656","article-title":"Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis","volume":"36","author":"Hostetler","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF125","first-page":"abstract 1161","article-title":"Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococal meningitis in AIDS patients","author":"Hamill","year":"1999","journal-title":"Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy."},{"key":"10.1054\/drup.2000.0171_RF126","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1128\/AAC.36.7.1466","article-title":"Aerolized liposomal amphotericin B for treatment of pulmonary and systemic cryptococcus neoformans infections in mice","volume":"36","author":"Gilbert","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF127","first-page":"177","article-title":"Chronic cryptococcal meningitis","volume":"101","author":"Perfect","year":"1980","journal-title":"Am J Pathol"},{"key":"10.1054\/drup.2000.0171_RF128","first-page":"561","article-title":"Experimental cryptococcosis: dissemination of Cryptococcus neoformans and dermotropism in guinea-pigs","volume":"29","author":"van Cutsem","year":"1986","journal-title":"Mykosen."},{"key":"10.1054\/drup.2000.0171_RF129","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1128\/AAC.33.10.1735","article-title":"Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304","volume":"33","author":"Perfect","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF130","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/AAC.36.1.217","article-title":"Comparison of SCH39304 and its isomers, RR 42427 and SS 42426, for treatment of murine cryptococcal and coccidioidal meningitis","volume":"36","author":"Allendoerfer","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF131","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1128\/AAC.40.8.1910","article-title":"In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans","volume":"40","author":"Perfect","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF132","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/AAC.41.4.863","article-title":"In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species,Cryptococcus neoformans, Blastomyces dermatitidis , and Aspergillus species","volume":"41","author":"Zhanel","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF133","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.44.3.739-746.2000","article-title":"Synergistic antifungal activities of bafilomycin A1, fluconazole, and the pneumocandin MK-0991\/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans","volume":"44","author":"Del Poeta","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF134","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1128\/AAC.39.8.1885","article-title":"Liposomal amphotericin B therapy of murine histoplasmosis","volume":"39","author":"Graybill","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF135","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1128\/AAC.42.1.151","article-title":"Treatment of histoplasmosis with MK-991 (L-743,872)","volume":"42","author":"Graybill","year":"1998","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1054\/drup.2000.0171_RF136","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/AAC.39.3.778","article-title":"Efficacy of the triazole D0870 in a murine model of systemic histoplasmosis","volume":"39","author":"Clemons","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF137","first-page":"768","article-title":"Treatment of murine histoplasmosis with UK 49,858 (fluconazole)","volume":"134","author":"Graybill","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"10.1054\/drup.2000.0171_RF138","first-page":"837","article-title":"Experimental chemotherapy of histoplasmosis in nude mice","volume":"120","author":"Williams","year":"1979","journal-title":"Am Rev Respir Dis"},{"key":"10.1054\/drup.2000.0171_RF139","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/ajrccm\/137.5.1193","article-title":"Experimental pulmonary histoplasmosis and emphysema","volume":"137","author":"Graybill","year":"1988","journal-title":"Am Rev Resp Dis"},{"key":"10.1054\/drup.2000.0171_RF140","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1128\/AAC.44.7.1850-1854.2000","article-title":"Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in the murine model","volume":"44","author":"Kohler","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF141","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.42.9.2371","article-title":"Efficacy of nikkomycin Z in the treatment of murine histoplasmosis","volume":"42","author":"Graybill","year":"1998","journal-title":"AntimicrobAgents Chemother"},{"key":"10.1054\/drup.2000.0171_RF142","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/clinids\/9.Supplement_1.S15","article-title":"Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models","volume":"9 Suppl","author":"van Cutsem","year":"1987","journal-title":"Rev Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF143","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1128\/AAC.31.12.2005","article-title":"Comparison of fluconazole and amphotericin B in treating histoplasmosis in immunosuppressed mice","volume":"31","author":"Kobayashi","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF144","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/AAC.34.4.587","article-title":"Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis","volume":"34","author":"Hector","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF145","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1128\/AAC.44.6.1624-1629.2000","article-title":"Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model","volume":"44","author":"Goldberg","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF146","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1128\/AAC.37.5.1177","article-title":"Activities of the triazole D0870 in vitro and against murine blastomycosis","volume":"37","author":"Clemons","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF147","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1128\/AAC.35.10.2144","article-title":"Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxcholate suspension against murine blastomycosis","volume":"35","author":"Clemons","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF148","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/AAC.40.5.1314","article-title":"In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis","volume":"40","author":"Sugar","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF149","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1128\/AAC.33.8.1391","article-title":"Evaluation of colifungin, a lipopeptide antifungal agent, in vitro against fungi isolated from clinical specimens","volume":"33","author":"Hanson","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF150","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1128\/AAC.41.9.2026","article-title":"Efficacy of nikkomycin Z against experimental pulmonary blastomycosis","volume":"41","author":"Clemons","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF151","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4269\/ajtmh.1998.58.424","article-title":"Experimental pulmonary fibrosis induced by Paracoccidioides brasilienseis conidia: measurement of local host responses","volume":"58","author":"Franco","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"10.1054\/drup.2000.0171_RF152","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1128\/IAI.63.5.1777-1783.1995","article-title":"Pulmonary paracoccidioidomycosis in resistant and susceptible mice: relationship among progression of infection, bronchoalveolar cell activation, cellular immune response, and specific isotype patterns","volume":"63","author":"Cano","year":"1995","journal-title":"Infect Immun"},{"key":"10.1054\/drup.2000.0171_RF153","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2249.1993.tb05980.x","article-title":"Experimental murine paracoccidioidomycosis: relationship among the dissemination of the infection, humoral and cellular immune responses","volume":"94","author":"Singer-Vermes","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1054\/drup.2000.0171_RF154","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1164\/arrd.1982.125.5.563","article-title":"Host defense against experimental paracoccidioidomysosis","volume":"125","author":"Robledo","year":"1982","journal-title":"Am Rev Respir Dis"},{"key":"10.1054\/drup.2000.0171_RF155","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/02681219680000671","article-title":"Cell-mediated immunity in host resistance against infection caused by Penicillium marneffei","volume":"34","author":"Kudeken","year":"1996","journal-title":"J Med Vet Mycol"},{"key":"10.1054\/drup.2000.0171_RF156","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/02681219780001401","article-title":"Histopathological and electron microscopical studies on experimental Penicillium marneffei infection in mice","volume":"35","author":"Cui","year":"1997","journal-title":"J Med Vet Mycol"},{"key":"10.1054\/drup.2000.0171_RF157","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM199504203321607","article-title":"Current concepts: Coccidioidomycosis","volume":"332","author":"Stevens","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1054\/drup.2000.0171_RF158","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/516118","article-title":"Editorial response: adequacy of therapy for coccicioidomycosis","volume":"25","author":"Stevens","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF159","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/02681219480000151","article-title":"Treatment of coccidioidomycosis with SCH39304","volume":"32","author":"Hostetler","year":"1994","journal-title":"J Med Vet Mycol"},{"key":"10.1054\/drup.2000.0171_RF160","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/02681219480000621","article-title":"Efficacy of AmBisome on murine coccidioidomycosis","volume":"32","author":"Albert","year":"1994","journal-title":"J Med Vet Mycol"},{"key":"10.1054\/drup.2000.0171_RF161","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/infdis\/162.4.944","article-title":"Activity of cilofungin against Coccidioides immitis: differential in vitro effects in mycelia and spherules correlated with in vivo studies","volume":"162","author":"Galgiani","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF162","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1128\/AAC.41.7.1558","article-title":"Activity of the triazole SCH56592 against disseminated murine coccidioidomycosis","volume":"41","author":"Lutz","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF163","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1128\/AAC.44.6.1512-1517.2000","article-title":"Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis","volume":"44","author":"Sorensen","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF164","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1128\/AAC.34.4.663","article-title":"Treatment of murine coccidioidal meningitis with SCH39304","volume":"34","author":"DeFaveri","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005792-198607000-00001","article-title":"Phaeohyphomycosis caused by the fungal genera Bipolaris and Exserohilum","volume":"65","author":"Adam","year":"1986","journal-title":"Medicine"},{"key":"10.1054\/drup.2000.0171_RF166","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1086\/513662","article-title":"Invasive mold sinusitis: 17 cases in immunocompromised patients and review of the literature","volume":"24","author":"Iwen","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF167","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0190-9622(90)70259-K","article-title":"Itraconazole treatment of phaeohyphomycosis","volume":"23","author":"Sharkey","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1054\/drup.2000.0171_RF168","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000238485","article-title":"In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis","volume":"33","author":"Dixon","year":"1987","journal-title":"Chemother."},{"key":"10.1054\/drup.2000.0171_RF169","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1128\/AAC.44.5.1159-1162.2000","article-title":"SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due toRamichloridium obovoideum (\u201cRamichloridium mackenziei\u201d)","volume":"44","author":"Al-Abdely","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF170","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00006123-199908000-00034","article-title":"Cerebral phaeohyphomycosis caused by Ramichloridium obovoideum (Ramichloridium mackenziei): case report","volume":"45","author":"Podnos","year":"1999","journal-title":"Neurosurgery"},{"key":"10.1054\/drup.2000.0171_RF171","first-page":"375","article-title":"Cerebral phaeohyphomycosis caused by Ramichloridium obovoideum (Ramichloridium mackenziei): case report \u2013 Comments","volume":"45","author":"Rock","year":"1999","journal-title":"Neurosurgery."},{"key":"10.1054\/drup.2000.0171_RF172","doi-asserted-by":"crossref","first-page":"651","DOI":"10.4269\/ajtmh.1989.40.651","article-title":"Experimental murine chromoblastomycosis mimicking chronic progressive human disease","volume":"40","author":"Ahrens","year":"1989","journal-title":"Am J Trop Med Hyg"},{"key":"10.1054\/drup.2000.0171_RF173","doi-asserted-by":"crossref","first-page":"601","DOI":"10.4269\/ajtmh.1990.42.601","article-title":"Treatment of chronic chromoblastomycosis with the triazole SCH39304","volume":"42","author":"DeFaveri","year":"1990","journal-title":"Am J Trop Med Hyg"},{"key":"10.1054\/drup.2000.0171_RF174","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1439-0507.1988.tb04410.x","article-title":"Experimental zygomycosis due to Rhizopus species infection by various routes in guinea-pigs, rats, and mice","volume":"31","author":"van Cutsem","year":"1988","journal-title":"Mycoses"},{"key":"10.1054\/drup.2000.0171_RF175","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.1989.301","article-title":"Effects of deferoxamine, ferroxamine and iron on experimental mucormycosis (zygomycosis)","volume":"36","author":"van Cutsem","year":"1989","journal-title":"Kidney International."},{"key":"10.1054\/drup.2000.0171_RF176","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/jcp.48.3.223","article-title":"Iron metabolism and fungal infections in patients with haematological malignancies","volume":"48","author":"Iglesias-Osma","year":"1995","journal-title":"J Clin Pathol"},{"key":"10.1054\/drup.2000.0171_RF177","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1550-7408.1999.tb05119.x","article-title":"The role of iron in protozoan and fungal infectious diseases","volume":"46","author":"Weinberg","year":"1999","journal-title":"J Euk Microbiol."},{"key":"10.1054\/drup.2000.0171_RF178","series-title":"Mycopathologia.","article-title":"Experimental zygomycosis in rabbits: clinicopathological studies","author":"Sondhi","year":"1998"},{"key":"10.1054\/drup.2000.0171_RF179","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/infdis\/165.6.1155","article-title":"Lack of activity of amphotericin B in systemic murine fusarial infection","volume":"165","author":"Anaissie","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF180","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1128\/AAC.43.3.589","article-title":"Treatment of murine fusariosis with SCH 56592","volume":"43","author":"Lozano-Chiu","year":"1999","journal-title":"AntimicrobAgents Chemother"},{"key":"10.1054\/drup.2000.0171_RF181","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1086\/515645","article-title":"Candidiasis in interferon-gamma knockout mice","volume":"1998","author":"Balish","year":"1998","journal-title":"J.Infect.Dis."},{"key":"10.1054\/drup.2000.0171_RF182","first-page":"2564","article-title":"Intrapulmonary response to Histoplasma capsulatum in gamma interferon knockout mice","volume":"65","author":"Allendoerfer","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF183","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1128\/IAI.62.7.2761-2772.1994","article-title":"Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis","volume":"62","author":"Louie","year":"1994","journal-title":"Infect Immun"},{"key":"10.1054\/drup.2000.0171_RF184","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/infdis\/171.2.406","article-title":"Fluconazole and amphotericin B antifungal therapies do not negate the protective effect of endogenous tumor necrosis factor in a murine model of fatal disseminated candidiasis","volume":"171","author":"Louie","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF185","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/infdis\/159.1.113","article-title":"Amphotericin B induces tumor necrosis factor production by murine macrophages","volume":"159","author":"Chia","year":"1989","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF186","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/516362","article-title":"Combination immunotherapy and antifungal chemotherapy","volume":"26","author":"Stevens","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF187","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4049\/jimmunol.155.2.785","article-title":"IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma","volume":"155","author":"Zhou","year":"1995","journal-title":"J Immunol"},{"key":"10.1054\/drup.2000.0171_RF188","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1046\/j.1365-2249.1996.14723.x","article-title":"IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans","volume":"104","author":"Kawakami","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1054\/drup.2000.0171_RF189","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1128\/IAI.64.9.3609-3613.1996","article-title":"Interleukin-12 regulation of host defenses against Coccidioides immitis","volume":"64","author":"Magee","year":"1996","journal-title":"Infect Immun"},{"key":"10.1054\/drup.2000.0171_RF190","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1128\/IAI.66.10.4994-5000.1998","article-title":"Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans","volume":"66","author":"Decken","year":"2000","journal-title":"Infect Immun"},{"key":"10.1054\/drup.2000.0171_RF191","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1086\/513989","article-title":"Modulation of immune responses in murine pulmonary histoplasmosis","volume":"175","author":"Allendoerfer","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF192","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1128\/AAC.38.3.460","article-title":"Cytokine treatment of a central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis","volume":"38","author":"Clemons","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF193","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/infdis\/170.5.1331","article-title":"In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis","volume":"170","author":"Joly","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF194","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/infdis\/169.2.369","article-title":"Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat","volume":"169","author":"Vitt","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF195","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/02681219780001221","article-title":"Granulocyte colony stimulating factor therapy of experimental murine cryptococcosis","volume":"35","author":"Graybill","year":"1997","journal-title":"J Med Vet Mycol"},{"key":"10.1054\/drup.2000.0171_RF196","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/BF01690878","article-title":"Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis","volume":"14","author":"Graybill","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF197","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1439-0507.1991.tb00645.x","article-title":"Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice","volume":"34","author":"Polak-Wyss","year":"1991","journal-title":"Mycoses."},{"key":"10.1054\/drup.2000.0171_RF198","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/jac\/35.4.509","article-title":"Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans","volume":"35","author":"Van Etten","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1054\/drup.2000.0171_RF199","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1128\/AAC.28.5.648","article-title":"Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans","volume":"28","author":"Humphrey","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF200","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/00362178485380721","article-title":"R 51211 (itraconazole) therapy of murine cryptococcosis","volume":"22","author":"Graybill","year":"1984","journal-title":"J Med Vet Mycol"},{"key":"10.1054\/drup.2000.0171_RF201","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/mmy.38.3.209.212","article-title":"Effect of grapefruit juice on serum voriconazole concentrations in the mouse","volume":"38","author":"Sugar","year":"2000","journal-title":"Med Mycol"},{"key":"10.1054\/drup.2000.0171_RF202","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1128\/AAC.41.3.696","article-title":"Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis","volume":"41","author":"Murphy","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF203","first-page":"abstract F73","article-title":"UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidiasis models and early clinical activity in oropharyngeal candidiasis","author":"Troke","year":"1995","journal-title":"Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy."},{"key":"10.1054\/drup.2000.0171_RF204","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1128\/AAC.44.3.727-731.2000","article-title":"Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys","volume":"44","author":"Nomeir","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF205","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1128\/AAC.36.1.56","article-title":"Efficacy of cilofungin therapy administered by continuous intravenous infusion for experimental disseminated candidiasis in rabbits","volume":"36","author":"Rouse","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF206","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1128\/AAC.35.7.1321","article-title":"Antifungal effects of the nonlinear pharmacokinetis of cilofungin, a 1,3-beta-D-glucan synthase inhibitor, during continuous and intermittent infusions in treatment of experimental disseminated candidiasis","volume":"35","author":"Walsh","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF207","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1128\/AAC.34.11.2240","article-title":"Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits","volume":"34","author":"Lee","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF208","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/02681219780001081","article-title":"Discrepancy between in vitro and in vivo antifungal activity of albendazole","volume":"35","author":"Hardin","year":"1997","journal-title":"J Med Vet Mycol"},{"key":"10.1054\/drup.2000.0171_RF209","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1164\/ajrccm\/139.1.8","article-title":"Treatment of murine cryptococcis with cyclosporin-A in normal and athymic mice","volume":"139","author":"Mody","year":"1989","journal-title":"Am Rev RespDis"},{"key":"10.1054\/drup.2000.0171_RF210","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1128\/IAI.50.1.22-26.1985","article-title":"Effects of cyclopsorine in experimental cryptococal meningitis","volume":"50","author":"Perfect","year":"1985","journal-title":"Infect Immun"},{"key":"10.1054\/drup.2000.0171_RF211","first-page":"abstract J-96","article-title":"Terbinafine treatment of cutaneous sporotrichosis:initial results from a phase II\/III trial","author":"Pappas","year":"1998","journal-title":"Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy."},{"key":"10.1054\/drup.2000.0171_RF212","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1128\/AAC.44.2.470-472.2000","article-title":"In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans","volume":"44","author":"Meletiadis","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF213","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1128\/AAC.41.8.1812","article-title":"In vitro activiteis of terbinafine in combination with fluconazole and itraonazole against isolates of Candida with reduced susceptibility to azoles","volume":"41","author":"Barchiesi","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF214","first-page":"abstract P556","article-title":"Efficacy of terbinafine (TER) alone or in combination with itraconazole (ITZ) against experimental pulmonary aspergillosis","author":"Clemons","year":"1997","journal-title":"Proceedings of the 13th Congress of the International Society for Human and Animal Mycology."},{"key":"10.1054\/drup.2000.0171_RF215","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/infdis\/151.5.902","article-title":"The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis","volume":"151","author":"Schaffner","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF216","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000238138","article-title":"Combination therapy of experimental candidiasis, cryptococcosis, and aspergillosis in mice","volume":"28","author":"Polak","year":"1982","journal-title":"Chemotherapy"},{"key":"10.1054\/drup.2000.0171_RF217","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/infdis\/149.4.650","article-title":"Treatment of murine pulmonary cryptococcosis with ketoconazole and amphotericin B","volume":"149","author":"Iwen","year":"1984","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF218","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000238524","article-title":"Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice","volume":"33","author":"Polak","year":"1987","journal-title":"Chemotherapy"},{"key":"10.1054\/drup.2000.0171_RF219","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF01639520","article-title":"Combination therapy for systemic mycosis","volume":"17","author":"Polak","year":"1989","journal-title":"Infection"},{"key":"10.1054\/drup.2000.0171_RF220","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1128\/AAC.39.3.598","article-title":"Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B","volume":"39","author":"Sugar","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF221","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1128\/AAC.35.8.1669","article-title":"Interactions of amphotericin B and SCH 39304 in the treatment of experimental murine candidiasis: lack of antagonism of a polyene-azole combination","volume":"35","author":"Sugar","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF222","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1086\/515319","article-title":"Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis","volume":"177","author":"Sugar","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF223","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199707033370103","article-title":"Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome","volume":"337","author":"Van der Horst","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1054\/drup.2000.0171_RF224","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1128\/AAC.39.9.1907","article-title":"Use of amphotericin B with azole antifungal drugs: What are we doing?","volume":"39","author":"Sugar","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF225","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/infdis\/131.2.129","article-title":"Combined activity of amphotericin B and 5-fluorcytosine against Cryptococcus neoformans in vitro and in vivo in mice","volume":"131","author":"Hamilton","year":"1975","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF226","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3181\/00379727-142-37049","article-title":"The combined effects of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis","volume":"142","author":"Block","year":"1973","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1054\/drup.2000.0171_RF227","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1128\/AAC.35.4.726","article-title":"Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis","volume":"35","author":"Allendoerfer","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF228","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1086\/515074","article-title":"Early mycological treatment failure in AIDS-associated cryptococcal meningitis","volume":"28","author":"Robinson","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF229","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/clinids\/19.4.741","article-title":"Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS","volume":"19","author":"Larsen","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF230","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/infdis\/173.5.1216","article-title":"Treatment of experimental cryptococcal meningitis with fluconazole: impact of dose and addition of flucytosine on mycologic and pathophysiologic outcome","volume":"173","author":"Kartalija","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1054\/drup.2000.0171_RF231","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.41.11.2326","article-title":"In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)","volume":"41","author":"Bartizal","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF232","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1128\/AAC.35.7.1329","article-title":"Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis","volume":"35","author":"Denning","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF233","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/AAC.35.7.1334","article-title":"Synergy between cilofungin and amphotericin B in a murine model of candidiasis","volume":"35","author":"Hanson","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF234","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1128\/AAC.43.6.1401","article-title":"In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole","volume":"43","author":"Li","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/drup.2000.0171_RF235","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1128\/AAC.36.6.1284","article-title":"Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo","volume":"36","author":"Hector","year":"1992","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764600901717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764600901717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T05:41:54Z","timestamp":1682142114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764600901717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":235,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["S1368764600901717"],"URL":"https:\/\/doi.org\/10.1054\/drup.2000.0171","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}